Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy

Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy

Intratumor heterogeneity leads to different responses to targeted therapies, even within patients whose tumors harbor identical driver oncogenes. This study examined clinical outcomes according to a patient-derived cell (PDC)-based drug sensitivity test in lung cancer patients treated with targeted...

Full description

Bibliographic Details
Main Authors: Sunshin Kim, Youngjoo Lee, Bo Ram Song, Hanna Sim, Eun Hye Kang, Mihwa Hwang, Namhee Yu, Sehwa Hong, Charny Park, Beung-Chul Ahn, Eun Jin Lim, Kum Hui Hwang, Seog-Yun Park, Jin-Ho Choi, Geon Kook Lee, Ji-Youn Han
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Cancers
Subjects:
patient-derived cell
targeted therapy
EGFR mutation
ALK fusion
lung cancer
predictive marker
Online Access:https://www.mdpi.com/2072-6694/16/4/778

Internet

https://www.mdpi.com/2072-6694/16/4/778

Similar Items